ATIM-40. HIGH RATE OF OBJECTIVE ANTI-TUMOR RESPONSE IN 9 PATIENTS WITH GLIOBLASTOMA AFTER VIRO-IMMUNOTHERAPY WITH ONCOLYTIC PARVOVIRUS H-1 IN COMBINATION WITH BEVACICUMAB AND PD-1 CHECKPOINT BLOCKADE

BACKGROUND: Combination therapy is an emerging concept to improve the clinical effects of oncolytic virus based anti-cancer strategies. In a phase I/IIa trial (ParvOryx01) the oncolytic H-1 parvovirus (H-1PV) induced markers of immune activation in patients with recurrent glioblastoma. The goal of t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Geletneky, Karsten, Bartsch, Andreas, Weiss, Christian, Bernhard, Helga, Marchini, Antonio, Rommelaere, Jean
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2018
Schlagworte:
Abstracts
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6216150/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.035
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge